The Putative Glyoxalase 1 Inhibitor Piceatannol Exhibits Both Anxiolytic-like and Antitumor Effects in Mice

Anticancer Res. 2020 Jun;40(6):3271-3276. doi: 10.21873/anticanres.14309.

Abstract

Background/aim: This study aimed to determine the anxiolytic effect of a putative glyoxalase 1 inhibitor, piceatannol, as well as its antitumor activities on the stress-induced tumor growth of Lewis lung carcinoma.

Materials and methods: The anxiolytic activities of piceatannol (1-30 mg/kg) were assessed using the elevated plus maze (EPM) test. We also evaluated the pharmacological modulation of stress-induced tumor growth; the mice were treated with piceatannol (3 and 30 mg/kg) from the 10th day till the 19th day after administration of the LLC cells.

Results: At the low dose (3 mg/kg), piceatannol significantly increased the time spent in the open arms of the EPM test when compared with the vehicle. At higher doses (30 mg/kg), it significantly suppressed the stress-induced enhancement of tumor growth.

Conclusion: A low dose of piceatannol exerts an anxiolytic effect, and high doses have an antitumor effect.

Keywords: Glyoxalase 1; antitumor effect; anxiolytic effect; piceatannol.

MeSH terms

  • Animals
  • Anti-Anxiety Agents / pharmacology
  • Anti-Anxiety Agents / therapeutic use*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Lactoylglutathione Lyase / antagonists & inhibitors*
  • Lactoylglutathione Lyase / therapeutic use
  • Male
  • Mice
  • Protein-Tyrosine Kinases / pharmacology
  • Protein-Tyrosine Kinases / therapeutic use*
  • Stilbenes / pharmacology
  • Stilbenes / therapeutic use*

Substances

  • Anti-Anxiety Agents
  • Antineoplastic Agents
  • Stilbenes
  • 3,3',4,5'-tetrahydroxystilbene
  • Protein-Tyrosine Kinases
  • Lactoylglutathione Lyase